Immunoconjugates and bispecific antibodies: Trends in therapeutic success and commercial focus.

Monoclonal antibodies (mAbs) have revolutionized the selective targeting of disease, as well as changing the character of the pharmaceutical industry. Although most attention has focused on conventional antibodies, immunoconjugates and bispecific antibodies (bsAbs) are beginning to show greater potential. Herein, we identify trends in the development and approval of antibody derivatives, as well as the organizations developing these products. Whereas industry development of immunoconjugates has grown steadily over four decades, momentum behind bispecific agents has seemingly expanded only recently. Together, our findings suggest that antibody derivatives provide interesting, albeit still speculative, opportunities for targeted interventions. Copyright © 2022 Elsevier Ltd. All rights reserved.

Citation

Michael S Kinch, Zachary Kraft, Tyler Schwartz. Immunoconjugates and bispecific antibodies: Trends in therapeutic success and commercial focus. Drug discovery today. 2023 Mar;28(3):103462

Mesh Tags

Substances

PMID: 36464142

search → result